Start with the structural number that matters: Novo Nordisk, a company more than a century old, now files its annual report with U.S. regulators as a foreign private issuer — on Form 20-F, not the 10-K American companies use. That single procedural fact tells you the GLP-1 era has made a Danish drugmaker a central name for U.S. investors.
Novo's Form 20-F filed February 5, 2025 is the document where the semaglutide franchise — the Ozempic and Wegovy family — is described in the language of regulated disclosure rather than marketing. For a U.S.-focused reader, the 20-F is the primary, English-language record of how the company frames its own metabolic business.
Here is what the form type itself signals, by the numbers. A 20-F is filed annually by non-U.S. companies; it consolidates the kind of risk, financial, and operational disclosure a 10-K carries. The fact that one is filed at all — and read closely by U.S. analysts — reflects how the GLP-1 demand wave pulled a European issuer into the center of the American biotech conversation. Three years ago, far fewer U.S. generalist investors were parsing Novo's annual filing line by line.
Be precise about correlation versus causation. The rise in attention to Novo's 20-F tracks the rise of the obesity-drug story — but a filing's prominence is a downstream signal, not a cause. What the document offers is the disciplined version of the narrative: the company's own framing of its metabolic franchise, filed under U.S. securities rules.
The methodological point for readers: when a foreign drugmaker becomes essential to a U.S. investment thesis, the right primary source is the 20-F, not the 10-K you would reach for with a domestic peer like Lilly. Matching the form type to the issuer is the difference between reading the record and reading the wrong document.
The EdgarBeast evidence index, which surfaces and normalizes SEC filings, makes it straightforward to locate a foreign issuer's 20-F alongside domestic 10-Ks. For Novo Nordisk in early 2025, the number to notice is the form number: 20-F — the annual record of a company the GLP-1 wave made central to U.S. portfolios.